Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer

T. Sugisaki, T. Aoyama, K. Kawakami, T. Yokokawa, K. Kobayashi, W. Suzuki, M. Ogura, T. Ichimura, K. Chin, K. Yamaguchi, S. Hanaoka, H. Hayashi, M. Yamaguchi

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

The use of cisplatin may cause nephrotoxicity in patients. Hydration solutions supplemented with magnesium could reduce cisplatin-induced nephrotoxicity. In this study, we evaluated the preventive effect of magnesium pre-loading on cisplatin-induced nephrotoxicity in patients with esophageal cancer. We retrospectively evaluated the prevalence of, and risk factors for, nephrotoxicity in 160 patients with esophageal cancer treated with the 5-fluorouracil/cisplatin regimen from 2014 to 2016 with and without magnesium supplementation. Significant differences were observed between the magnesium and non-magnesium groups in terms of frequency of estimated creatinine clearance of grade 2 or higher that was at 4% (n = 3) and 13% (n = 10) (p = 0.027), respectively. The logistic regression analysis revealed that eCcr of grade 2 or higher was significantly associated with the non-magnesium regimen (odds ratio (OR), 4.175; 95% confidence interval (CI) = 1.061–16.430; p = 0.041) and age ≥ 65 years (OR, 13.951; 95% CI = 1.723–112.974; p = 0.014). This study suggests that 20 mEq magnesium pre-loading significantly reduces the prevalence of cisplatin-induced nephrotoxicity. Furthermore, when cisplatin is administered to individuals older than 64 years, a close observation for the onset of cisplatin-induced nephrotoxicity is crucial.

Original languageEnglish
Pages (from-to)85-88
Number of pages4
JournalPharmazie
Volume77
Issue number2
DOIs
Publication statusPublished - Feb 2022

Fingerprint

Dive into the research topics of 'Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer'. Together they form a unique fingerprint.

Cite this